RhoVac's vaccine product RV001 recognises cells with high concentration of RhoC protein, which is a characteristic of most types of metastatic cancer cells, and stimulates the immune system to target them. The company's concept focuses on eliminating cancer cells having metastatic potential that escape treatment of the parent tumour via other methods. RhoVac is based in Sweden and Denmark, publicly traded in the Swedish stock market, and managed by a senior team of executives with extensive expertise in immunotherapy on therapeutic cancer vaccines.